Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey. (Q51505589)

6 April 2018

title

Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey. (English)

1 reference

6 April 2018

1 reference

15

1 reference

6 April 2018

author name string

A Simon

1

1 reference

6 April 2018

E Müllenborn

2

1 reference

6 April 2018

M Prelog

3

1 reference

6 April 2018

W Schenk

4

1 reference

6 April 2018

J Holzapfel

5

1 reference

6 April 2018

F Ebinger

6

1 reference

6 April 2018

A Klabunde-Cherwon

7

1 reference

6 April 2018

J Faber

8

1 reference

6 April 2018

A H Groll

9

1 reference

6 April 2018

K Masjosthusmann

10

1 reference

6 April 2018

C Dohna-Schwake

11

1 reference

6 April 2018

K Beutel

12

1 reference

6 April 2018

E Dirkwinkel

13

1 reference

6 April 2018

T Lehrnbecher

14

1 reference

6 April 2018

A Müller

16

1 reference

6 April 2018

publication date

3 November 2011

1 reference

6 April 2018

European Journal of Clinical Microbiology & Infectious Diseases

published in

1 reference

6 April 2018

volume

31

1 reference

6 April 2018

page(s)

1435-1442

1 reference

6 April 2018

issue

7

1 reference

6 April 2018

https://scigraph.springernature.com/pub.10.1007/s10096-011-1461-1

exact match

0 references

cites work

Antibiotic-resistant bugs in the 21st century--a clinical super-challenge

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid for the treatment of complicated skin and skin structure infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Experience with linezolid therapy in children with osteoarticular infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

The past, present, and future of healthcare‐associated infection prevention in pediatrics: multidrug‐resistant organisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Targeted surveillance to identify children colonized with vancomycin-resistant Enterococcus in the pediatric intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Unrecognized burden of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus carriage in the pediatric intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

The use of linezolid in the treatment of paediatric patients with infections caused by enterococci including strains resistant to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid: the first oxazolidinone antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Use of linezolid in pediatrics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Off-label antibiotic use in children in three European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Methicillin-resistant Staphylococcus aureus endocarditis in an extremely low-birth-weight infant treated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Pharmacological issues of linezolid: an updated critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid treatment of shunt-related cerebrospinal fluid infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Epidemiology, prevention and management of ventriculoperitoneal shunt infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid cerebrospinal fluid concentration in central nervous system infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Update on the safety of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Peripheral neuropathy in an adolescent treated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid-induced optic neuropathy: a mitochondrial disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Auditory nerve neuropathy in a neonate after linezolid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Fosfomycin: use beyond urinary tract and gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Single dose pharmacokinetics of linezolid in infants and children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Impact of ontogeny on linezolid disposition in neonates and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid pharmacokinetics in pediatric patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Antimicrobial prescription errors in hospitalized children: role of antimicrobial stewardship program in detection and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid in the treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Benefit-risk assessment of linezolid for serious gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1461-1

Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22048844

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22048844

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22048844

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10096-011-1461-1

1 reference

6 April 2018

PubMed ID

22048844

1 reference

6 April 2018